中西医结合防治肝硬化SBP和内毒素血症

目的：观察中西医结合防治肝硬化自发性细菌性腹膜炎（SBP）和内毒素血症（IETM）的临床效果。方法：将90例乙型肝炎后肝硬化患者随机分为三组，每组30例。对照组予以常规治疗，培菲康组在常规治疗的同时加用培菲康胶囊口服，联合组在培菲康组治疗基础上服用中药“承气合剂”。疗程3个月，分别观察三组自发性细菌性腹膜炎发生率和血内毒素水平变化。结果：培菲康组和联合组在疗程结束时血清内毒素水平明显下降（P〈0．05），联合组尤为显著（P〈0．01）。联合组SBP发生率较对照组显著降低（P〈0．05）。结论：培菲康胶囊联合承气合剂增强肝硬化患者肠道屏障功能，能有效减少SBP发生率和IETM水平。

Treating Liver Cirrhosis Spontaneous bacterial peritonitis and Lipopolysaccaride by Integrated Traditional Chinese and Western Medicine

Objective:To observe the curative effect of integrated traditional Chinese and western medicine on treating liver cirrhosis spontaneous bacterial peritonitis (SBP) and intestinalendotoxemia (IETM). Methods: 90 cases with liver cirrhosis induced by hepatitis B were randomly divided into three groups, with 30 cases in each group. The contrast group was treated by normal methods, the Bifid Triple Viable group by Bifid Triple Viable capsules on the base of routine treatment and the combination group by Bifid Triple Viable capsules and tradition Chinese medicine of Chengqiheji decoction on the base of routine treatment. The period of therapy was 3 months. The occurred ratio of SBP and change of IETM level were investigated. Results: The levels of serum IETM in the Bifid Triple Viable group and combination group were decreased (P<0.05). That change in the combination group was more obviously (P<0.01). The occurred ratio of SBP in the combination group was significantly reduced (P<0.05) compared with that in the contrast group (P<0.05). Conclusion: Bifid Triple Viable capsules combined with Chengqiheji can improve the barrier function of intestine in patients with liver cirrhosis, and effectively decrease the occurred ratio of SBP and the level of IETM.